What is Perspective Therapeutics, Inc.'s earnings per share (EPS)?

Perspective Therapeutics, Inc. (CATX) reported diluted earnings per share of -$1.40 for fiscal year 2025. This represents a -13.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Perspective Therapeutics, Inc. (CATX) Financials

CATX

FY2025 annual

Net Income -$103.1M -30.1% YoY

EPS (Diluted) -$1.40 -13.8% YoY

Free Cash Flow -$95.2M -31.0% YoY

Operating Cash Flow -$82.5M -350.9% YoY

Market Cap $269.4M as of Oct 6, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.8x on $323.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CATX SEC filings page.

This page shows Perspective Therapeutics, Inc. (CATX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CATX FY2025 2026-10-04

Perspective Therapeutics is still a development-stage business: research spending drives losses, while financing—not operating revenue—supports its balance sheet.

The key shift is cash conversion: in FY2024, a net loss of $79.3M accompanied operating cash flow of -$18.3M, but in FY2025 the net loss of $103.1M came closer to operating cash flow of -$82.5M. That narrowing gap means the latest accounting loss translated more directly into cash consumption, leaving less separation between reported earnings and funding needs.

Research intensity is accelerating: R&D rose from $41.6M in FY2024 to $84.2M in FY2025. Operating loss also widened from $90.9M to $113.6M, indicating that the company’s current cost base is being shaped more by development investment than by commercial scale.

The balance sheet is primarily equity-funded: total liabilities were $59.9M against $267.0M of assets. Debt-to-equity was just 0.0x, while the reported liquidity measure equaled 21.1 months of the latest annual operating outflow, showing substantially more reliance on capital reserves than borrowing.

Financial Health Signals

Financial health score not available

Perspective Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Perspective Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Perspective Therapeutics, Inc. reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$28.1M

YoY-20.6%

QoQ-3.5%

Perspective Therapeutics, Inc.'s EBITDA was -$28.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.

Net Income

-$26.8M

YoY-24.7%

QoQ-2.3%

Perspective Therapeutics, Inc. reported -$26.8M in net income in Q2 2026. This represents a decrease of 24.7% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.

EPS (Diluted)

-$0.22

QoQ+12.0%

Perspective Therapeutics, Inc. earned -$0.22 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 12.0%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$34.8M

YoY-66.1%

QoQ+9.1%

Perspective Therapeutics, Inc. recorded an outflow of $34.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 66.1% from the same quarter a year earlier. Against the prior quarter it is up 9.1%.

Cash & Debt

$48.5M

YoY+68.1%

QoQ-10.2%

5Y CAGR-5.3%

10Y CAGR+16.9%

Perspective Therapeutics, Inc. held $48.5M in cash against $1.6M in long-term debt as of Q2 2026.

Shares Outstanding

114M

QoQ+0.1%

5Y CAGR-4.3%

10Y CAGR+7.6%

Perspective Therapeutics, Inc. had 114M shares outstanding in Q2 2026. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-8.3%

YoY-0.2pp

QoQ-0.7pp

Perspective Therapeutics, Inc.'s ROE was -8.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$21.5M

YoY+29.6%

QoQ+0.8%

Perspective Therapeutics, Inc. invested $21.5M in research and development in Q2 2026. This represents an increase of 29.6% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Capital Expenditures

$14.2M

YoY+1283.5%

QoQ+107.0%

5Y CAGR+162.0%

10Y CAGR+51.8%

Perspective Therapeutics, Inc. invested $14.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1283.5% from the same quarter a year earlier. Against the prior quarter it is up 107.0%.

Share Buybacks

Not reported for Q2 2026.

CATX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	$1.4M-76.8%	$6.2M-38.5%	$10.1M+3.9%	$9.7M+32.3%	$7.3M+23.5%	$5.9M+24.4%	$4.8M-0.2%	$4.8M+3.5%	$4.6M+9.2%	$4.2M-6.8%	$4.5M-10.8%	$5.1M-3.2%	$5.2M
Cost of Revenue	N/A	N/A	N/A	N/A	$6.2M+25.3%	$4.9M+8.3%	$4.6M+6.8%	$4.3M+4.6%	$4.1M+4.0%	$3.9M-15.5%	$4.6M+4.5%	$4.4M+0.5%	$4.4M+0.9%	$4.4M+0.2%	$4.4M+7.0%	$4.1M
Gross Profit	N/A	N/A	N/A	$1.4M	$0-100.0%	$5.1M-0.1%	$5.1M+68.2%	$3.0M+65.4%	$1.8M+119.8%	$838K+549.6%	$129K-22.8%	$167K+185.0%	-$196K-230.8%	$150K-78.6%	$703K-39.2%	$1.2M
R&D Expenses	N/A	$84.2M+102.3%	$41.6M+95.4%	$21.3M+2319.0%	$881K-38.3%	$1.4M+26.7%	$1.1M-23.6%	$1.5M-15.6%	$1.7M+80.9%	$965K+82.8%	$528K-14.1%	$615K-8.0%	$669K+6.6%	$627K-19.7%	$781K-20.4%	$981K
SG&A Expenses	N/A	$30.2M+13.6%	$26.6M+26.3%	$21.1M+181.4%	$7.5M+59.6%	$4.7M+2.6%	$4.6M+9.6%	$4.2M+0.2%	$4.2M+6.3%	$3.9M+3.5%	$3.8M+57.7%	$2.4M-3.5%	$2.5M+8.5%	$2.3M-2.6%	$2.4M-2.8%	$2.4M
Operating Income	N/A	-$113.6M-25.0%	-$90.9M-122.0%	-$40.9M-372.1%	-$8.7M-151.7%	-$3.4M+0.9%	-$3.5M+33.8%	-$5.3M+21.9%	-$6.7M-6.7%	-$6.3M-24.1%	-$5.1M-17.2%	-$4.3M+5.5%	-$4.6M-12.8%	-$4.1M-13.0%	-$3.6M-21.4%	-$3.0M
EBITDA	N/A	-$110.3M-24.5%	-$88.6M-121.7%	-$40.0M-375.8%	-$8.4M-157.6%	-$3.3M+0.9%	-$3.3M+35.1%	-$5.1M+23.2%	-$6.6M-5.8%	-$6.2M-35.3%	-$4.6M-22.6%	-$3.8M+3.6%	-$3.9M-17.3%	-$3.3M-21.0%	-$2.8M-32.6%	-$2.1M
Interest Expense	N/A	N/A	N/A	$84K	$0	N/A	N/A	N/A	N/A	$0-100.0%	$1K-50.0%	$2K+126.5%	$883+12514.3%	$7-100.0%	$62K-71.5%	$217K
Income Tax	N/A	-$793K+62.2%	-$2.1M+20.9%	-$2.7M	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A
Net Income	N/A	-$103.1M-30.1%	-$79.3M-70.5%	-$46.5M-332.2%	-$10.8M-217.7%	-$3.4M+1.7%	-$3.4M+33.0%	-$5.1M+23.2%	-$6.7M-8.7%	-$6.2M-30.8%	-$4.7M-28.0%	-$3.7M+38.2%	-$6.0M-54.5%	-$3.9M-10.5%	-$3.5M-22.8%	-$2.8M
EPS (Basic)	N/A	-$1.40-13.8%	-$1.23+29.3%	-$1.74-2075.0%	-$0.08-166.7%	-$0.03+40.0%	-$0.05	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.40-13.8%	-$1.23	-$1.74	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	74M+14.6%	64M	27M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$21.5M+29.6%	$21.4M+49.1%	N/A	$20.3M+69.1%	$16.6M+79.2%	$14.3M+92.3%	N/A	$12.0M+116.6%
SG&A Expenses	$7.8M+1.1%	$7.0M-10.9%	N/A	$7.7M+10.8%	$7.7M+39.8%	$7.8M+33.4%	N/A	$7.0M+55.9%
Operating Income	-$29.3M-21.7%	-$28.3M-29.5%	N/A	-$27.9M-49.5%	-$24.0M-68.5%	-$21.8M-67.9%	N/A	-$18.6M-91.1%
EBITDA	-$28.1M-20.6%	-$27.2M-28.7%	N/A	-$27.1M-50.8%	-$23.3M-70.2%	-$21.1M-66.8%	N/A	-$18.0M-89.3%
Net Income	-$26.8M-24.7%	-$26.2M-44.1%	N/A	-$26.0M-71.7%	-$21.5M-83.6%	-$18.2M-48.0%	N/A	-$15.1M-46.0%
EPS (Basic)	-$0.22+24.1%	-$0.250.0%	-$0.51+16.4%	-$0.35-66.7%	-$0.29-61.1%	-$0.250.0%	-$0.61+33.0%	-$0.21+43.2%
EPS (Diluted)	-$0.22	-$0.250.0%	-$0.51+16.4%	-$0.35-66.7%	-$0.29-61.1%	-$0.25	-$0.61	-$0.21
Diluted Shares (Avg)	121M	104M+43.2%	N/A	74M+5.2%	74M+11.4%	72M	N/A	71M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

CATX Balance Sheet

CATX quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$267.0M-21.7%	$341.1M+248.4%	$97.9M+68.5%	$58.1M-17.5%	$70.4M+709.5%	$8.7M-7.7%	$9.4M+26.4%	$7.5M-39.2%	$12.3M-32.2%	$18.1M-21.3%	$23.0M-13.4%	$26.5M+276.3%	$7.1M-6.0%	$7.5M-4.9%	$7.9M
Current Assets	$148.4M-35.8%	$231.2M+1272.9%	$16.8M-68.4%	$53.2M-20.9%	$67.3M+1122.1%	$5.5M-24.7%	$7.3M+34.3%	$5.4M-47.1%	$10.3M-24.5%	$13.6M-16.5%	$16.3M-15.0%	$19.2M+332.4%	$4.4M+7.4%	$4.1M-2.0%	$4.2M
Cash & Equivalents	$30.6M-50.3%	$61.6M+566.6%	$9.2M-56.0%	$21.0M-67.1%	$63.8M+2568.4%	$2.4M-55.1%	$5.3M+104.8%	$2.6M-56.2%	$5.9M-41.5%	$10.1M+94.0%	$5.2M-31.9%	$7.7M+164.8%	$2.9M+8.5%	$2.7M+26.5%	$2.1M
Short-Term Investments	$114.1M-31.0%	$165.3M	$0-100.0%	$22.8M	$0	$0	$0-100.0%	$825K-72.9%	$3.0M+35.2%	$2.2M-76.0%	$9.4M-6.4%	$10.0M	$0	$0	$0
Inventory	N/A	N/A	N/A	$1.4M+43.8%	$980K+51.9%	$645K+21.7%	$530K+7.3%	$494K+52.9%	$323K-3.3%	$334K-17.3%	$404K+12.3%	$360K-11.3%	$406K-8.7%	$444K-40.7%	$750K
Accounts Receivable	$6K-94.8%	$116K-90.0%	$1.2M-14.5%	$1.4M-32.3%	$2.0M	N/A	N/A	N/A	N/A	N/A	$1.0M+14.9%	$913K-1.2%	$924K+6.8%	$865K+9.1%	$793K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$3.0M-41.8%	$5.1M-5.5%	$5.4M	$0	$0	$0
Goodwill	N/A	$0-100.0%	$24.1M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$59.9M+18.9%	$50.4M+122.1%	$22.7M+558.5%	$3.4M+14.6%	$3.0M+1.1%	$3.0M+70.8%	$1.7M-28.2%	$2.4M+45.5%	$1.7M-2.0%	$1.7M-23.4%	$2.2M-14.4%	$2.6M+53.5%	$1.7M+0.1%	$1.7M+17.5%	$1.4M
Current Liabilities	$28.7M+57.3%	$18.2M+16.4%	$15.7M+402.4%	$3.1M+73.1%	$1.8M+14.3%	$1.6M+40.5%	$1.1M-38.9%	$1.8M+65.9%	$1.1M+1.1%	$1.1M+0.2%	$1.1M-5.3%	$1.2M+45.5%	$793K+22.2%	$649K-16.2%	$774K
Non-Current Liabilities	$31.3M-2.9%	$32.2M+356.9%	$7.0M+2029.3%	$331K-72.6%	$1.2M-13.7%	$1.4M+125.6%	$621K+5.3%	$590K+5.2%	$561K-7.6%	$607K-46.2%	$1.1M-21.6%	$1.4M+60.6%	$896K-13.7%	$1.0M+56.8%	$662K
Long-Term Debt	$1.6M-3.1%	$1.7M-2.8%	$1.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$207.0M-28.8%	$290.7M+286.6%	$75.2M+37.6%	$54.6M-18.9%	$67.4M+1077.8%	$5.7M-25.5%	$7.7M+52.7%	$5.0M-52.6%	$10.6M-35.4%	$16.4M-21.1%	$20.8M-13.2%	$24.0M+346.4%	$5.4M-7.8%	$5.8M-9.8%	$6.5M
Retained Earnings	-$334.8M-44.5%	-$231.7M-52.0%	-$152.4M-43.9%	-$105.9M-16.0%	-$91.3M-3.9%	-$87.9M-4.1%	-$84.5M-6.5%	-$79.3M-9.3%	-$72.6M-9.3%	-$66.4M-7.6%	-$61.7M-6.3%	-$58.1M-11.4%	-$52.1M-8.0%	-$48.2M-7.8%	-$44.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$392.0M+26.2%	$410.8M+24.7%	$267.0M-21.7%	$294.8M-24.6%	$310.7M-19.5%	$329.3M+18.3%	$341.1M+248.4%	$391.2M+253.9%
Current Assets	$241.5M+23.3%	$275.4M+27.6%	$148.4M-35.8%	$178.5M-33.9%	$196.0M-33.4%	$215.7M+14.6%	$231.2M+1272.9%	$270.2M+1145.7%
Cash & Equivalents	$48.5M+68.1%	$54.0M+21.5%	$30.6M-50.3%	$26.8M-88.2%	$28.8M-88.6%	$44.4M-68.8%	$61.6M+566.6%	$226.4M+1159.2%
Short-Term Investments	$188.4M+15.8%	$217.0M+29.7%	$114.1M-31.0%	$147.4M+255.9%	$162.7M+298.2%	$167.3M+334.2%	$165.3M	$41.4M
Accounts Receivable	$269K+19.6%	$58K-25.6%	$6K-94.8%	$179K-17.5%	$225K+58.5%	$78K-92.2%	$116K-90.0%	$217K-87.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$24.1M-11.9%
Total Liabilities	$68.2M+51.4%	$63.3M+41.7%	$59.9M+18.9%	$52.6M-16.1%	$45.0M+0.2%	$44.7M-7.6%	$50.4M+122.1%	$62.7M+433.6%
Current Liabilities	$36.5M+181.4%	$31.5M+148.3%	$28.7M+57.3%	$20.6M-26.7%	$13.0M+22.4%	$12.7M-12.6%	$18.2M+16.4%	$28.1M+246.8%
Non-Current Liabilities	$31.6M-1.3%	$31.8M-0.6%	$31.3M-2.9%	$32.0M-7.4%	$32.0M-6.6%	$32.0M-5.5%	$32.2M+356.9%	$34.5M+850.7%
Long-Term Debt	$1.6M-3.3%	$1.6M-3.2%	$1.6M-3.1%	$1.6M-3.0%	$1.7M-3.2%	$1.7M-2.9%	$1.7M-2.8%	$1.7M-2.8%
Total Equity	$323.9M+21.9%	$347.4M+22.1%	$207.0M-28.8%	$242.2M-26.3%	$265.7M-22.1%	$284.6M+23.8%	$290.7M+286.6%	$328.5M+232.6%
Retained Earnings	-$387.8M-42.9%	-$361.0M-44.5%	-$334.8M-44.5%	-$297.4M-55.2%	-$271.4M-53.8%	-$249.9M-51.7%	-$231.7M-52.0%	-$191.6M-49.9%

Not reported in any period shown, so not listed: Inventory.

CATX Cash Flow Statement

CATX quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$93.1M	-$82.5M-350.9%	-$18.3M+50.4%	-$36.9M-254.9%	-$10.4M-266.6%	-$2.8M+22.1%	-$3.6M+27.9%	-$5.0M+11.6%	-$5.7M0.0%	-$5.7M-47.1%	-$3.9M-10.3%	-$3.5M-9.1%	-$3.2M-5.6%	-$3.1M-24.9%	-$2.4M-1.2%	-$2.4M
Depreciation & Amortization	N/A	$3.3M+41.0%	$2.3M+133.9%	$986K+259.9%	$274K+47.3%	$186K+0.5%	$185K-0.5%	$186K+43.1%	$130K+91.2%	$68K-85.6%	$471K-18.2%	$576K-16.0%	$685K-7.3%	$739K-12.7%	$847K-4.7%	$889K
Stock-Based Compensation	N/A	$9.0M+66.4%	$5.4M+44.1%	$3.7M+280.3%	$983K+154.7%	$386K-22.0%	$495K+17.9%	$420K+4.0%	$404K+8.6%	$372K+28.3%	$290K+41.5%	$205K+10.2%	$186K+71.7%	$108K-37.5%	$173K-28.6%	$243K
Capital Expenditures	$28.1M	$12.7M-76.6%	$54.4M+4975.9%	$1.1M+280.1%	$282K-26.0%	$381K+39.6%	$273K-38.5%	$444K+31.8%	$337K-38.6%	$549K+14.6%	$479K+260.2%	$133K+598.9%	$19K+189.4%	$7K-88.1%	$55K-60.0%	$137K
Free Cash Flow	-$121.2M	-$95.2M-31.0%	-$72.7M-91.4%	-$38.0M-255.6%	-$10.7M-232.0%	-$3.2M+17.8%	-$3.9M+28.7%	-$5.5M+9.2%	-$6.0M+3.4%	-$6.3M-43.5%	-$4.4M-19.4%	-$3.7M-12.6%	-$3.2M-6.0%	-$3.1M-22.4%	-$2.5M+2.1%	-$2.6M
Investing Cash Flow	-$52.0M	$41.2M+118.8%	-$218.9M-998.3%	$24.4M+184.1%	-$29.0M-6970.2%	-$410K-42.9%	-$287K-171.6%	$401K-78.4%	$1.9M+22.8%	$1.5M-82.7%	$8.8M	N/A	N/A	-$13K+86.6%	-$96K+39.5%	-$158K
Financing Cash Flow	$164.7M	$10.3M-96.4%	$289.4M+36764.3%	$785K+2703.6%	$28K-100.0%	$64.7M+6407.4%	$994K-86.5%	$7.4M+1315.4%	$521K+5888.9%	-$9K-123.1%	$39K	N/A	N/A	$3.3M+6.2%	$3.1M+3.1%	$3.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$20.6M-3.5%	-$31.5M-45.8%	-$24.7M+7.3%	-$16.3M-584.0%	-$20.0M-124.1%	-$21.6M-255.8%	-$26.6M-195.4%	$3.4M+133.3%
Depreciation & Amortization	$1.1M+55.7%	$1.1M+53.8%	$1.0M+42.6%	$775K+15.8%	$733K+28.1%	$732K+105.6%	$709K	$669K+158.3%
Stock-Based Compensation	$3.0M+26.8%	$2.6M+21.7%	N/A	$2.2M+10.5%	$2.4M+309.4%	$2.1M+219.8%	N/A	$2.0M+367.0%
Capital Expenditures	$14.2M+1283.5%	$6.9M+47.3%	$5.1M-65.3%	$2.0M-93.3%	$1.0M+1.1%	$4.7M-48.7%	$14.6M+16320.2%	$29.7M+12989.4%
Free Cash Flow	-$34.8M-66.1%	-$38.3M-46.1%	-$29.7M+27.9%	-$18.3M+30.6%	-$21.0M-111.5%	-$26.2M-649.4%	-$41.2M-353.1%	-$26.3M-154.9%
Investing Cash Flow	$15.0M+252.2%	-$109.6M-1868.6%	$28.5M+120.6%	$14.0M+147.1%	$4.3M+229.4%	-$5.6M+88.2%	-$138.6M-155632.6%	-$29.7M-13000.0%
Financing Cash Flow	$147K+11.4%	$164.4M+1548.1%	-$13K-103.8%	$213K-66.1%	$132K-99.9%	$10.0M-94.0%	$345K-2.0%	$628K+62700.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CATX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	100.0%+100.0pp	0.0%-50.9pp	50.9%-2.0pp	52.9%+11.3pp	41.7%+10.6pp	31.1%+13.5pp	17.6%+14.9pp	2.7%-0.9pp	3.6%+8.3pp	-4.7%-8.0pp	3.3%-10.5pp	13.9%-8.2pp	22.1%
Operating Margin	N/A	N/A	-2855.0%	-140.3%	-34.3%+1.6pp	-35.9%+35.9pp	-71.8%	-113.6%	-132.5%	-106.6%	-94.2%	-108.7%	-89.9%-18.9pp	-71.0%-14.4pp	-56.6%
Net Margin	N/A	N/A	-3243.2%	-174.1%	-33.7%+1.9pp	-35.6%+34.7pp	-70.3%	-113.1%	-129.4%	-98.8%-18.9pp	-79.9%	-141.2%	-85.2%-16.4pp	-68.8%-14.5pp	-54.3%
Return on Equity	-49.8%-22.5pp	-27.3%+34.6pp	-61.9%-42.2pp	-19.7%-14.7pp	-5.0%+55.2pp	-60.2%+6.8pp	-67.0%+66.2pp	-133.2%-75.1pp	-58.1%-29.4pp	-28.7%-11.0pp	-17.7%+7.2pp	-24.9%+47.0pp	-71.9%-11.9pp	-60.0%-15.9pp	-44.0%
Return on Assets	-38.6%-15.4pp	-23.2%+24.3pp	-47.5%-29.0pp	-18.5%-13.7pp	-4.8%+34.8pp	-39.6%+15.0pp	-54.6%+35.3pp	-89.9%-39.7pp	-50.2%-24.2pp	-26.0%-10.0pp	-16.0%+6.5pp	-22.4%+32.2pp	-54.7%-8.2pp	-46.5%-10.4pp	-36.0%
Current Ratio	5.17-7.5x	12.68+11.6x	1.07-16.0x	17.07-20.3x	37.37+33.9x	3.50-3.0x	6.53+3.6x	2.97-6.3x	9.30-3.2x	12.46-2.5x	14.95-1.7x	16.65+11.0x	5.60-0.8x	6.37+0.9x	5.45
Debt-to-Equity	0.010.0x	0.010.0x	0.020.0x	0.060.0x	0.04-0.5x	0.52+0.3x	0.23-0.3x	0.48+0.3x	0.16+0.1x	0.100.0x	0.110.0x	0.11-0.2x	0.310.0x	0.29+0.1x	0.22
Asset Turnover	N/A	N/A	0.01-0.1x	0.110.0x	0.14-1.0x	1.11+0.3x	0.780.0x	0.79+0.4x	0.39+0.1x	0.26+0.1x	0.200.0x	0.16-0.5x	0.640.0x	0.680.0x	0.66
FCF Margin	N/A	N/A	-2648.9%	-172.9%	-32.0%+8.4pp	-40.4%+34.7pp	-75.1%	-102.1%	-131.5%	-91.5%-12.1pp	-79.3%-2.4pp	-77.0%-9.3pp	-67.7%-18.3pp	-49.4%-0.6pp	-48.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-8.3%-0.2pp	-7.5%-1.1pp	N/A	-10.7%-6.1pp	-8.1%-4.7pp	-6.4%-1.0pp	N/A	-4.6%+5.9pp
Return on Assets	-6.8%+0.1pp	-6.4%-0.9pp	N/A	-8.8%-4.9pp	-6.9%-3.9pp	-5.5%-1.1pp	N/A	-3.9%+5.5pp
Current Ratio	6.61-8.5x	8.75-8.3x	5.17-7.5x	8.66-0.9x	15.09-12.6x	17.02+4.0x	12.68+11.6x	9.60+6.9x
Debt-to-Equity	0.000.0x	0.000.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Perspective Therapeutics, Inc. CATX	FY2025	N/A	-$103.1M	N/A	$269.4M	—
TriSalus Life Sciences, Inc. TLSI	FY2025	$45.2M	-$39.2M	-86.9%	$269.7M	50/100
Outset Medical, Inc. OM	FY2025	$119.5M	-$81.7M	-68.3%	$77.1M	61/100
Quantum-Si Incorporated QSI	FY2025	$2.4M	-$101.3M	N/A	$280.2M	58/100
Cerus Corp CERS	FY2025	$233.8M	-$15.6M	-6.7%	$471.6M	37/100
NANO-X IMAGING LTD NNOX	FY2025	$13.0M	-$75.0M	N/A	$50.5M	54/100

Where Perspective Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Perspective Therapeutics, Inc. profitable?

No, Perspective Therapeutics, Inc. (CATX) reported a net income of -$103.1M in fiscal year 2025.

What is Perspective Therapeutics, Inc.'s EBITDA?

Perspective Therapeutics, Inc. (CATX) had EBITDA of -$110.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Perspective Therapeutics, Inc. have?

As of fiscal year 2025, Perspective Therapeutics, Inc. (CATX) had $30.6M in cash and equivalents against $1.6M in long-term debt.

What is Perspective Therapeutics, Inc.'s return on equity (ROE)?

Perspective Therapeutics, Inc. (CATX) has a return on equity of -49.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Perspective Therapeutics, Inc.'s free cash flow?

Perspective Therapeutics, Inc. (CATX) recorded an outflow of $95.2M in free cash flow during fiscal year 2025. This represents a -31.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Perspective Therapeutics, Inc.'s operating cash flow?

Perspective Therapeutics, Inc. (CATX) recorded an outflow of $82.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Perspective Therapeutics, Inc.'s total assets?

Perspective Therapeutics, Inc. (CATX) had $267.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Perspective Therapeutics, Inc.'s capital expenditures?

Perspective Therapeutics, Inc. (CATX) invested $12.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Perspective Therapeutics, Inc. spend on research and development?

Perspective Therapeutics, Inc. (CATX) invested $84.2M in research and development during fiscal year 2025.

How many shares does Perspective Therapeutics, Inc. have outstanding?

Perspective Therapeutics, Inc. (CATX) had 114M shares outstanding as of fiscal year 2025.

What is Perspective Therapeutics, Inc.'s current ratio?

Perspective Therapeutics, Inc. (CATX) had a current ratio of 5.17 as of fiscal year 2025, which is generally considered healthy.

What is Perspective Therapeutics, Inc.'s debt-to-equity ratio?

Perspective Therapeutics, Inc. (CATX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Perspective Therapeutics, Inc.'s return on assets (ROA)?

Perspective Therapeutics, Inc. (CATX) had a return on assets of -38.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Perspective Therapeutics, Inc.'s P/E ratio?

Perspective Therapeutics, Inc. (CATX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $269.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Perspective Therapeutics, Inc.'s price-to-sales ratio?

Perspective Therapeutics, Inc. (CATX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $269.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Perspective Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Perspective Therapeutics, Inc. (CATX) held $144.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $82.5M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Perspective Therapeutics, Inc.'s Piotroski F-Score?

Perspective Therapeutics, Inc. (CATX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Perspective Therapeutics, Inc.'s earnings high quality?

Perspective Therapeutics, Inc. (CATX) reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.